Table 4.
Proportion of patients experiencing first and sustained improvement events in the WOMAC domains during study 3a.
| N | Pain |
Physical Function |
Stiffness |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| First n (%) | Sustained n (%) | First to Sustained (%)b | First n (%) | Sustained n (%) | First to Sustained (%)b | First n (%) | Sustained n (%) | First to Sustained (%)b | ||
| 15% | ||||||||||
| NSAIDs | 997 | 885 (88.8) | 836 (83.9) | 94.5 | 870 (87.3) | 833 (83.6) | 95.7 | 876 (87.9) | 824 (82.6) | 94.1 |
| TNZ 2.5 mg | 992 | 891 (89.8) | 833 (84.0) | 93.5 | 886 (89.3) | 834 (84.1) | 94.1 | 895 (90.2) | 837 (84.4) | 93.5 |
| TNZ 5 mg |
993 |
892 (89.8) |
851 (85.7) |
95.4 |
889 (89.5) |
844 (85.0) |
94.9 |
881 (88.7) |
828 (83.4) |
94.0 |
| 30% | ||||||||||
| NSAIDs | 997 | 789 (79.1) | 704 (70.6) | 89.2 | 791 (79.3) | 704 (70.6) | 89.0 | 799 (80.1) | 711 (71.3) | 89.0 |
| TNZ 2.5 mg | 992 | 784 (79.0) | 742 (74.8) | 94.6 | 786 (79.2) | 729 (73.5) | 92.7 | 803 (80.9) | 738 (74.4) | 91.9 |
| TNZ 5 mg |
993 |
806 (81.2) |
735 (74.0) |
91.2 |
796 (80.2) |
726 (73.1) |
91.2 |
801 (80.7) |
731 (73.6) |
91.3 |
| 50% | ||||||||||
| NSAIDs | 997 | 657 (65.9) | 563 (56.5) | 85.7 | 646 (64.8) | 564 (56.6) | 87.3 | 677 (67.9) | 564 (56.6) | 83.3 |
| TNZ 2.5 mg | 992 | 667 (67.2) | 574 (57.9) | 86.1 | 662 (66.7) | 578 (58.3) | 87.3 | 686 (69.2) | 576 (58.1) | 84.0 |
| TNZ 5 mg |
993 |
693 (69.8) |
589 (59.3) |
85.0 |
682 (68.7) |
588 (59.2) |
86.2458 |
709 (71.4) |
587 (59.1) |
82.8 |
| 70% | ||||||||||
| NSAIDs | 997 | 470 (47.1) | 347 (34.8) | 73.8 | 458 (45.9) | 343 (34.4) | 74.9 | 490 (49.1) | 359 (36.0) | 73.3 |
| TNZ 2.5 mg | 992 | 483 (48.7) | 375 (37.8) | 77.6 | 474 (47.8) | 360 (36.3) | 75.9 | 496 (50.0) | 349 (35.2) | 70.4 |
| TNZ 5 mg | 993 | 508 (51.2) | 376 (37.9) | 74.0 | 486 (48.9) | 363 (36.6) | 74.7 | 516 (52.0) | 380 (38.3) | 73.6 |
NSAID = nonsteroidal anti-inflammatory drugs, TNZ = tanezumab.
a
The 15%, 30%, 50%, and 70% thresholds were selected as representative, clinically meaningful thresholds of improvement.
b
First to sustained shows, among patients experiencing a first event, the proportion who experienced a sustained event (calculated as sustained n divided by first n).